Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
PROGRESSION OF ALZHEIMERS DISEASE (AD) Mild Cognitive Impairment (preclinical) MMSE 2630; CDR 0.5; FAST 3; MOCA< 26*
Report by patient or caregiver of memory loss Objective signs of memory impairment Mild construction, language, or executive dysfunction No functional impairment 6%15% annual conversion rate to dementia syndrome Some cases of mild cognitive impairment may not progress to AD
Middle, Moderate Impairment (yr 28) MMSE 1120; CDR 2; FAST 56*
Disordered to date, place Comprehension difficulties (aphasia) Impaired new learning Impaired calculating skills Getting lost in familiar places Problems with dressing, grooming Not cooking, shopping, banking Restless, anxious, depressed Delusions, agitation, aggression
Early, Mild Impairment (yr 13 from onset of symptoms) MMSE 2125; CDR 1; FAST 4*
Disoriented to date Naming difficulties (anomia) Recent recall problems Mild difficulty copying figures Problems managing finances Decreased insight Irritability, mood change Social withdrawal
DEMENTIA SYNDROME
Chronic acquired decline in memory and in at least one other cognitive function (eg,language, visual-spatial, executive) sufficient to affect dailylife.
* MMSE = Mini-Mental State Examination; CDR = Clinical Dementia Rating Scale; FAST = Reisberg Functional Assessment Staging Scale; MoCA = Montreal Cognitive Assessment
NEUROPSYCHIATRIC SYMPTOMS
Consider superimposed delirium or pain as precipitating factor.
Possible Risks
Delirium Head trauma Heavy smoking Hypercholesterolemia Hypertension Lower educational level Other genes Postmenopausal hormone therapy
Depressive Symptoms
Seen in up to 40% of AD patients; may precede onset of AD May cause acceleration or decline if untreated; suspect if patient stops eating orwithdraws Sadness Loss of interest in usual activities Anxiety and irritability
Possible Protections
Currently there are no proven preventive measures to stop the onset of Alzheimers disease. Antioxidants (eg, vitamin E, beta carotene) may provide possible protection. Use caution with vitamin E in those with cardiovascular disease because 400 IU may increase mortality.
Apathy
High prevalence and persistence throughout course of AD Causes more impairment in ADL than expected for cognitive status High overlap with depressive symptoms but lacks depressive mood, guilt, and hopelessness
Agitation or Aggression
Seen in up to 80% of patients with AD A leading cause of nursing-home admission
TREATMENT
Primary goals are to improve quality of life and maximize functional performance by enhancing cognition and addressing mood and behavior. Although completely reversible dementia (eg, drug toxicity) is rare, identifying and treating secondary physical conditions may improve function.
Nonpharmacologic Approaches
Advise caregiver(s) to: Use scheduled toileting and prompted toileting for incontinence. Offer graded assistance (as little help as possible to perform ADLs), role modeling, cueing, and positive reinforcement to increase independence. Avoid adversarial debates; try to redirect conversation instead. Maintain a calm demeanor. Use services of caregiver support groups. For problem behaviors: Music during meals, bathing Walking or light exercise Simulate family presence with video or audio tapes Pet therapy Speak at patients comprehension level Bright light, white noise (ie, lowlevel, background noise)
Neuropsychologic Testing
Reference standard for the presence of dementia or mild cognitive impairment: Especially helpful in mild, early disease and atypical presentations Quantifies and establishes the type of cognitive deficits Establishes baseline for comparison
Laboratory Testing
Complete blood cell count, thyroid-stimulating hormone, B12, folate, serum calcium, liver and kidney function tests, electrolytes Serologic test for syphilis (selectively) Glucose and HIV for patients at risk Genetic testing and Alzheimer blood tests are not currently recommended for clinical use.
DIAGNOSIS OF AD
Dementia syndrome Gradual onset and continuing decline Not due to another physical, neurologic, or psychiatric condition or to medications Deficits not seen exclusively during delirium
A GUIDE to DEMENTIA DIAGNOSIS andTREATMENT, page 3 Table 1. Cognitive Enhancers Medication Dosage
Donepezil (Aricept )a, b
Start at 5mg/d, increase to 10mg/d after 1 mo; must be on 10 mg/d for at least 3 mo to consider increasing to 23 mg/d Galantamine Start at 4mg q12h, increase to 8mg q12h after 4 wk; (Razadyne)a, c recommended dosage 8 or 12mg q12h (RazadyneER )a, c Start at 1 capsule daily, preferably with food; titrate as above Rivastigmine (Exelon) a Start at 1.5mg q12h and gradually titrate up to minimally effective dosage of 3mg q12h; continue up to 6mgq12h as tolerated; for patch, start at 4.6mg/d, may be increased after 4 wk to 9.5mg/d (recommended effective dosage): retitrate if medication is stopped Memantine (Namenda Start at 5mg/d, increase by 5mg at weekly intervals [NMDAantagonist]) b to max of 10mg q12h; if CrCl <30mL/min, max dose is 5mg q12h
Cholinesterase inhibitors. FDA labeling for AD is as follows: donepezilmild, moderate, severe; galantaminemild, moderate; rivastigminemild, moderate. Continue if patient improves or stabilizes; stopping medication can lead to rapid decline. Adverse events increase with higher dosage. Possible adverse events include nausea, vomiting, diarrhea, dyspepsia, anorexia, weight loss, leg cramps, bradycardia, syncope, insomnia, and agitation. b Approved by FDA for moderate to severe AD. Possible adverse events include dizziness, headache, somnolence.NMDA = N-methyl-d-aspartate. c Increased mortality found in controlled studies of mild cognitive impairment.
a
Agitation in context of depression Anxiety, mild to moderate irritability Agitation or aggression unresponsive to first-line treatment Sexual aggression, impulsecontrol symptoms in men
Buspirone 1560 mg/db Trazodone 50100 mg/dc Carbamazepine 300600 mg/dd Divalproex sodium 5001500 mg/de Olanzapine (intramuscular) 2.55 mg IMa, f Second-generation antipsychotic or divalproex (seedosages above) If no response, conjugated equine estrogens 0.6251.25 mg/d or medroxyprogesterone injectable 100mg/wk IM
Greater mortality and cerebrovascular events than placebo; use with particular caution in patients with cerebrovascular disease or hypovolemia. b Can be given q12h; allow 24 wk for adequate trial. c Small divided daytime dosage and larger bedtime dosage; watch for sedation and orthostasis. d Monitor serum levels; periodic CBCs, platelet counts secondary to agranulocytosis risk. Beware of drug-drug interactions. e Can monitor serum levels; usually well tolerated; check complete blood count (CBC), platelets for agranulocytosis, thrombocytopenia risk. f For acute use only; initial dose 2.55mg, second dose (2.55mg) can be given after 2 hr, maximum of 3 injections in 24 hr (maximum daily dose 20mg); should not be administered for more than 3 consecutive days.
a
Treatment of Agitation
Consider nonpharmacologic approaches first. Identify and examine context of behavior (is it harmful to patient or others?) and environmental triggers (eg, overstimulation, unfamiliar surroundings, frustrating interactions). Are delusions or hallucinations interfering with function? Exclude underlying physical discomfort (eg, illnesses or medications). For intermittent disruptive behaviors (once per week or less), identifying antecedents of the behavior and avoiding triggers is often most useful. Behavior modification using positive reinforcement of desirable behavior has been shown to be effective, and also helps caregiver focus on times when behavior is not a problem. Physical restraint in any form should be avoided if at all possible. If restraining measures are necessary, careful supportive care should be provided to the patient. Over time, it is usually possible to reduce or eliminate the amount of restraint. Select pharmacologic agent on the basis of symptoms (Table 2). Cognitive enhancers may slow deterioration, and agitation may worsen if they are discontinued. Low dosages of antipsychotic medications have a limited role but may be necessary at times. Note: this use is off label; use in AD patients has a BLACK BOX warning because the risk of death was higher with drug treatment than with placebo in clinical trials. Riskbenefit must be discussed with both patients and caregivers before starting treatment. In the CATIE-AD trial (NEJM 2006;355:15251538), modest treatment with second-generation antipsychotics showed no significant benefit (p=0.22). Olanzapine, risperidone, and quetiapine had marginally higher response rates (32%, 29%, and 26%, respectively) than placebo (21%). Response was mitigated by greater extrapyramidal symptoms, sedation, and confusion in the treated groups. Weight gain was reported, particularly in women treated with olanzapine and quetiapine. Olanzapine was also associated with decreased HDL cholesterol.
REFERENCES
Barton C, Yaffe K. Dementia. In: Pacala JT, Sullivan GM, eds. Geriatrics Review Syllabus: A Core Curriculum in Geriatric Medicine. 7th ed. New York: American Geriatrics Society; 2010:274-285. Lantz MS, Khanmohamadi A, Wong PY. Behavioral problems in dementia. In: Pacala JT, Sullivan GM, eds. Geriatrics Review Syllabus: A Core Curriculum in Geriatric Medicine. 7th ed. New York: American Geriatrics Society; 2010:285-294. Reuben DB, Herr KA, Pacala JT, Pollock BG, Potter JF, Semla TP. Dementia. In: Geriatrics At Your Fingertips: 2011. 13th ed (in production). New York: The American Geriatrics Society.
The Mini-CogTM screen combines an uncued 3-item recall test with a clock-drawing test (CDT) that serves as a recall distractor. The Mini-Cog can be administered in about 3 min, requires no special equipment, and is less influenced by level of education or languagedifferences.
Administration
1. Make sure you have the patients attention. Instruct the patient to listen carefully to, repeat back to you, and remember (now and later) 3unrelatedwords. You may present the same words up to 3 times if necessary. 2. Instruct the patient to draw the face of a clock, either on a blank sheet of paper, or on a sheet with the clock circle already drawn on the page. After the patient puts the numbers on the clock face, ask him or her to draw the hands of the clock to read a specific time (11:10 or 8:20 are most commonly used; however, other times that require use of both halves of the clock face my be effective). These instructions can be repeated, but no additional instructions should be given. If the patient cannot complete the CDT in 3 min or less, move on to the nextstep. 3. Ask the patient to repeat the 3 previously presented words.
Choose the best answer for how you felt over the past week. 1. Are you basically satisfied with your life? yes/no 2. Have you dropped many of your activities and interests? yes/no 3. Do you feel that your life is empty? yes/no 4. Do you often get bored? yes/no 5. Are you in good spirits most of the time? yes/no 6. Are you afraid that something bad is going to happen to you? yes/no 7. Do you feel happy most of the time? yes/no 8. Do you often feel helpless? yes/no 9. Do you prefer to stay at home, rather than going out and doing new things? yes/no 10. Do you feel you have more problems with memory than most? yes/no 11. Do you think it is wonderful to be alive now? yes/no 12. Do you feel pretty worthless the way you are now? yes/no 13. Do you feel full of energy? yes/no 14. Do you feel that your situation is hopeless? yes/no 15. Do you think that most people are better off than you are? yes/no
Scoring
Score 1 point for each bolded answer. Cut-off: normal 05; above 5 suggests depression.
Scoring
Give 1 point for each recalled word after the CDT distractor. Score03forrecall. Give 2 points for a normal CDT, and 0 points for an abnormal CDT. The CDT is considered normal if all numbers are depicted, once each, in the correct sequence and position, and the hands readably display the requested time. Do not count equal hand length as an error. Add the recall and CDT scores together to get the Mini-Cog score: 02 positive screen for dementia 35 negative screen for dementia
FAST Stage Activity Limitation Associated with AD Stage 1 No difficulty, either subjectively or objectively Stage 2 Complains of forgetting location of objects; subjective work difficulties Stage 3 Decreased job functioning evident to coworkers; difficulty in traveling to new locations Stage 4 Decreased ability to perform complex tasks (eg, planning dinner for guests, handling finances) Stage 5 Requires assistance in choosing proper clothing Stage 6 Decreased ability to dress, bathe, and toilet independently Substage 6a Difficulty putting clothing on properly Substage 6b Unable to bathe properly, may develop fear of bathing Substage 6c Inability to handle mechanics of toileting (ie, forgets to flush, does not wipe properly) Substage 6d Urinary incontinence Substage 6e Fecal incontinence Stage 7 Loss of speech, locomotion, and consciousness Substage 7a Ability to speak limited (15words a day) Substage 7b All intelligible vocabulary lost Substage 7c Nonambulatory Substage 7d Unable to smile Substage 7e Unable to hold head up
Source: Reisberg, B. Functional assessment staging (FAST), Psychopharmacol Bull 1988;24(4):653659. Copyright MedWorks Media Global, LLC. Reprinted with permission.
Source: Adapted from Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The Mini-Cog: acognitive vital signs measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry 2000; 15(11):10211027, and Borson S, Scanlan JM, Watanabe J, Tu SP, Lessig M. Improving identification of cognitive impairment in primary care. Int J Geriatr Psychiatry 2006; 21(4):349355. Reprinted with permission of S. Borson. Mini-Cog Copyright 2000, 2006, 2007. All rights reserved. Licensed for print distribution by S.Borson, MD, solely use as a clinical aid. Any other use is strictly prohibited. To obtain information on the Mini-CogTM contact Dr. Borson at soob@u.washington.edu.
Source: Courtesy of Jerome A. Yesavage, MD. For 30 translations of the GDS, see www.stanford.edu/~yesavage/GDS.html For additional information on administration and scoring, refer to the following references: Sheikh JI, Yesavage JA. Geriatric Depression Scale: recent evidence and development of a shorter version. Clin Gerontol 1986;5:165172. Feher EP, Larrabee GJ, Crook TH 3rd. Factors attenuating the validity of the Geriatric Depression Scale in a dementia population. J Am Geriatr Soc 1992;40:906909. Yesavage JA, Brink TL, Rose TL et al. Development and validation of a geriatric depression rating scale: a preliminary report. J Psychiatr Res 1983;17:27.